Hepatitis C treatment in dialysis patients: is a new dawn approaching?

Affiliations

¹ Boston University Medical Center, Boston, Massachusetts. Electronic address: craig.gordon@bmc.org.
² Boston University Medical Center, Boston, Massachusetts.

Comment

Craig E Gordon et al. Am J Kidney Dis. 2014 Aug.

. 2014 Aug;64(2):178-80.

doi: 10.1053/j.ajkd.2014.04.005. Epub 2014 May 3.

¹ Boston University Medical Center, Boston, Massachusetts. Electronic address: craig.gordon@bmc.org.
² Boston University Medical Center, Boston, Massachusetts.

No abstract available

Comment on

Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH. Liu CH, et al. Ann Intern Med. 2013 Dec 3;159(11):729-38. doi: 10.7326/0003-4819-159-11-201312030-00005. Ann Intern Med. 2013. PMID: 24297189 Clinical Trial.